Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia

Blood

Volumn 121, Issue 15, 2013, Pages 3005-3015

  Such, Esperanza ^a   Germing, Ulrich ^b   Malcovati, Luca ^c   Cervera, José ^a   Kuendgen, Andrea ^b   Della Porta, Matteo G ^c   Nomdedeu, Benet ^a,d   Arenillas, Leonor ^a,e   Luño, Elisa ^a,f   Xicoy, Blanca ^a,g   Amigo, Mari L ^a,h   Valcarcel, David ^a,i   Nachtkamp, Kathrin ^b   Ambaglio, Ilaria ^c   Hildebrandt, Barbara ^b   Lorenzo, Ignacio ^a   Cazzola, Mario ^c   Sanz, Guillermo ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF PAVIA   (Italy)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h HOSPITAL MORALES MESEGUER   (Spain)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHRONIC MYELOMONOCYTIC LEUKEMIA; CMML SPECIFIC PROGNOSTIC SCORING SYSTEM; COHORT ANALYSIS; DISEASE ASSOCIATION; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; VALIDATION STUDY; WORLD HEALTH ORGANIZATION; ACUTE DISEASE; BLOOD; GENETICS; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELOID LEUKEMIA; OUTCOME ASSESSMENT; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; STATISTICS; SURVIVAL; VERY ELDERLY;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBINS; HUMANS; LEUKEMIA, MYELOID; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

MLCS; MLOWN;

EID: 84877069358     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-452938     Document Type: Article

References (31)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189-199. (Pubitemid 12073508)
2. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukemia. Proposals by the French-American-British Cooperative leukemia group. Br J Haematol. 1994;87:746-754. (Pubitemid 24264647)
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088. (Pubitemid 27132124)
4. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454-2465.
5. Vardiman JW, Pierre R, Bain B, et al. Chronic myelomonocytic leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:49-51.
6. Orazi A, Bennett JM, Germing U, et al. Chronic myelomonocytic leukaemia. In: Swerdlow S, Campos E, Lee Harris N, et al, eds. WHO Classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC press, World Health Organization; 2008:76-81.
7. Such E, Cervera J, Costa D, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011;96(3):375-383.
8. Germing U, Strupp C, Aivado M, et al. New prognostic parameters for chronic myelomonocytic leukemia. Blood. 2002;100(2):731-732, author reply 732-733.
9. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99(3):840-849. (Pubitemid 34525544)
10. Worsley A, Oscier DG, Stevens J, et al. Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol. 1988;68(1):17-21. (Pubitemid 18051936)
11. González-Medina I, Bueno J, Torrequebrada A, et al. Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. Leuk Res. 2002;26(9):821-824. (Pubitemid 34778496)
12. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503-3510. (Pubitemid 47315575)
13. Shaffer LG, Slovak ML, Campbell LJ. An International System for Human Cytogenetic Nomenclature (2009): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 2009.
14. Gonen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika. 2005;92:965-970. (Pubitemid 41681247)
15. Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011;96(10):1433-1440.
16. Germing U, Gattermann N, Minning H, et al. Problems in the classification of CMML - dysplastic versus proliferative type. Leuk Res. 1998;22(10):871-878. (Pubitemid 28438295)
17. Orazi A, Germing U. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia. 2008;22(7):1308-1319.
18. Voglová J, Chrobák L, Neuwirtová R, et al. Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia - distinct subgroups or two stages of the same disease? Leuk Res. 2001;25(6):493-499. (Pubitemid 32409328)
19. Nösslinger T, Reisner R, Koller E, et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood. 2001;98(10):2935-2941.
20. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594-7603. (Pubitemid 46291823)
21. Beran M, Wen S, Shen Y, et al. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma. 2007;48(6):1150-1160. (Pubitemid 47009205)
22. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113(6):1351-1361.
23. Cazzola M, Malcovati L, Invernizzi R. Myelodysplastic/Myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2011;2011:264-272.
24. Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood. 2012;120(15):3080- 3088.
25. Kohlmann A, Grossmann V, Klein HU, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28(24):3858-3865.
26. Jankowska AM, Makishima H, Tiu RV, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011;118(14):3932-3941.
27. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-69.
28. Smith AE, Mohamedali AM, Kulasekararaj A, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood. 2010;116(19):3923-3932.
29. Makishima H, Visconte V, Sakaguchi H, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood. 2012;119(14):3203-3210.
30. Malcovati L, Papaemmanuil E, Bowen DT, et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011;118(24):6239-6246.
31. Kar SA, Jankowska A, Makishima H, et al. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica. 2013;98(1):107-113.